secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2026-06-25T12:00:40+00:00
Accession:  0001493152-26-030033
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MIRA Pharma reports preclinical data showing Mira-55 differentiated from THC, anxiolytic effect
--------------------------------------------------------------------------------

- Mira-55 did not produce THC-like locomotor suppression or catalepsy in standard preclinical assays.
- Modest body temperature reduction from Mira-55 was not reversed by CB1 antagonist rimonabant, indicating distinct mechanism.
- Mira-55 demonstrated anxiolytic activity, in contrast to anxiogenic activity of rimonabant; THC showed no anxiolysis.
- Data builds on March 2026 results; company advancing Mira-55 toward IND for chronic inflammatory pain.
- No psychoactivity or CNS side effects observed; candidate designed to avoid THC liabilities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000149315226030033/0001493152-26-030033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000149315226030033/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-030033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer